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Background of Study
HIV infection accelerates the rate of HCV progression to
fibrosis which represents the main factor affecting the
prognosis of hepatitis C as well the best indicator of dis-
ease status. There is increasing evidence that liver fibrosis
is a dynamic pathology c process in which the altered bal-
ance between matrix metalloproteiases (MMPs) and their
specific inhibitors (TIMPs) may play a major role.
Objective of the Study
To investigate the possible involvement of MMP-9 and
TIMP-1 in the HCV liver disease progression in patients
co-infected with HIV, we assessed the levels of circulating
enzyme and inhibitor in a series of HIV-infected individ-
uals with and without chronic hepatitis C.
Design
Study participants included a total of 76 HIV-infected
patients, of whom 49 without HCV infection (median
CD4 = 241/mmc;VL = 5 log) and 27 co-infected with HCV
(median CD4 = 130/mmc; VL = 5.3 log). All but one of
HIV/HCV co-infected patients had evidence of chronic
hepatitis C. 11 healthy donors were used as controls. Con-
centrations (ng/ml) of human TIMP-1 and MMP-9 were
detected in plasma samples using the Biotrak ELISA assay
(Amersham). Data are expressed as median.
Results
All HIV-infected patients had plasma TIMP-1 levels signif-
icantly higher than healthy controls (1740 vs. 755),
whereas MMP-9 levels were lower (23 vs. 1157) (p <
0.001). The levels of TIMP-1 were significantly higher in
patients with CD4 > 300/mmc than those with CD4 <
300/mmc (p < 0.05). No statistically significant differ-
ences in the levels of MMP-9 and in the TIMP-1/MMP-9
ratio were found between HCV co-infected and not co-
infected HIV+ patients (p < 0.05).
Conclusion
Our results suggest that the altered balance between
MMP-9 and TIMP-1 during HIV infection may play an
important role in exacerbating fibrosis progression in
patients co-infected with HCV.
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